Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 2Myeloid 2Classical hematology 1

Conditions

Myelodysplastic Syndromes 1Cytopenia 1

Interventions

Cyclophosphamide 17fludarabine phosphate 14Whole-Body Irradiation 11Mycophenolic Acid 9Epoetin Alfa 9Cyclosporine 9Busulfan 9fludarabine 8Cord Blood Stem Cell Transplantation 8Antilymphocyte Serum 8Filgrastim 6Tacrolimus 5Radiotherapy 5Peripheral Blood Stem Cell Transplantation 5Methotrexate 5Darbepoetin alfa 5Dalteparin 5Cytarabine 5eltrombopag 4Tinzaparin 4Thiotepa 4Platelet Transfusion 4Melphalan 4Etoposide 4Arsenic Trioxide 4thymoglobulin 3epoetin beta 3Vorinostat 3Transplantation 3Methylprednisolone 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × cedazuridine × Classical hematology × Clear all
NCT05148234 2025-09-30

BMS-986253 in Myelodysplastic Syndromes

National Institutes of Health Clinical Center (CC)

Phase 1/2 Terminated
2 enrolled 11 charts
Classical hematologyMyeloid

Cytopenia, Myelodysplastic Syndromes

Data powered by HemOnc (CC BY 4.0) Colophon âš¡